Pancreatic Neuroendocrine Tumors (PNETs): Incidence, Prognosis and Recent Trend Toward Improved Survival

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2008 Jun 3

PMID 18515795

Citations 331

Authors

T R Halfdanarson

K G Rabe

J Rubin

G M Petersen

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms that can present with symptoms of hormone overproduction. We evaluated the incidence, prognosis, and temporal trends of PNETs.

Patients And Methods: We analyzed all cases of PNETs registered in the Surveillance, Epidemiology, and End Results database from 1973 to 2000. Age-adjusted incidence and survival rates were calculated and survival trends over time were evaluated.

Results: We identified 1483 cases of PNETs. The crude annual incidence per 1,000,000 was 1.8 in females and 2.6 in males and increased with advancing age. The incidence increased over the study period. Most patients (90.8%) had nonfunctional tumors. Advanced stage, higher grade, and age were the strongest predictors of worse survival. Patients with functional tumors had better outcomes than patients with nonfunctional tumors in both univariate and multivariate analysis (P = 0.004). Survival time increased over the period from 1973 to 2000. No differences were seen in the distribution of stage or age at diagnosis among time periods.

Conclusion: PNETs are uncommon neoplasms but the incidence may be increasing. Age, grade, stage, and functional status predict survival in patients with PNETs. Survival has improved over time, but this is not explained by earlier diagnosis or stage migration.

Citing Articles

Gastroenteropancreatic Neuroendocrine Tumors: Does Tumor Location Affect Prognosis?.

Ozsoy M, Erol C, Aydemir M, Baysal H, Buyuker F, Seneldir H Arch Iran Med. 2025; 28(1):29-39.

PMID: 40001327 PMC: 11862391. DOI: 10.34172/aim.33366.

Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.

van T Veld B, Hackeng W, Luchini C, Brosens L, Dreijerink K Endocr Pathol. 2025; 36(1):3.

PMID: 39954168 PMC: 11829919. DOI: 10.1007/s12022-025-09848-1.

Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors.

Kenney L, Hughes M Cancers (Basel). 2025; 17(3).

PMID: 39941746 PMC: 11816225. DOI: 10.3390/cancers17030377.

Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma.

Chandra S, Halfdanarson T, Carlson E, Rabe K, Mahipal A, Majumder S Endocr Relat Cancer. 2025; 32(4).

PMID: 39932006 PMC: 11896652. DOI: 10.1530/ERC-24-0142.

Refractory hypercalcemia caused by parathyroid-hormone-related peptide secretion from a metastatic pancreatic neuroendocrine tumor: a case report.

Haimi M, Yang J, Kremer R J Med Case Rep. 2025; 19(1):54.

PMID: 39924477 PMC: 11809048. DOI: 10.1186/s13256-025-05074-9.

References

Kimura W, Kuroda A, Morioka Y . Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991; 36(7):933-42. DOI: 10.1007/BF01297144. View

Vortmeyer A, Huang S, Lubensky I, Zhuang Z . Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004; 89(4):1934-8. DOI: 10.1210/jc.2003-031575. View

MOLDOW R, Connelly R . Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968; 55(6):677-86. View

Sarmiento J, Heywood G, Rubin J, Ilstrup D, Nagorney D, Que F . Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197(1):29-37. DOI: 10.1016/S1072-7515(03)00230-8. View

Grimelius L, HULTQUIST G, Stenkvist B . Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol. 1975; 365(4):275-88. DOI: 10.1007/BF00471177. View

Aparicio T, Ducreux M, Baudin E, Sabourin J, de Baere T, Mitry E . Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001; 37(8):1014-9. DOI: 10.1016/s0959-8049(01)00073-9. View

White T, Edney J, Thompson J, KARRER F, Moor B . Is there a prognostic difference between functional and nonfunctional islet cell tumors?. Am J Surg. 1994; 168(6):627-9; discussion 629-30. DOI: 10.1016/s0002-9610(05)80134-5. View

Sarmiento J, Que F . Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003; 12(1):231-42. DOI: 10.1016/s1055-3207(02)00076-5. View

Touzios J, Kiely J, Pitt S, Rilling W, Quebbeman E, Wilson S . Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005; 241(5):776-83. PMC: 1357132. DOI: 10.1097/01.sla.0000161981.58631.ab. View

10.

Thompson G, Van Heerden J, Grant C, Carney J, Ilstrup D . Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988; 104(6):1011-7. View

11.

Sarmiento J, Farnell M, Que F, Nagorney D . Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg. 2002; 26(10):1267-71. DOI: 10.1007/s00268-002-6714-9. View

12.

Lepage C, Bouvier A, Phelip J, Hatem C, Vernet C, Faivre J . Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004; 53(4):549-53. PMC: 1774002. DOI: 10.1136/gut.2003.026401. View

13.

Carriaga M, Henson D . Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995; 75(1 Suppl):171-90. DOI: 10.1002/1097-0142(19950101)75:1+<171::aid-cncr2820751306>3.0.co;2-2. View

14.

Fesinmeyer M, Austin M, Li C, De Roos A, Bowen D . Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(7):1766-73. DOI: 10.1158/1055-9965.EPI-05-0120. View

15.

Kloppel G, Heitz P . Pancreatic endocrine tumors. Pathol Res Pract. 1988; 183(2):155-68. DOI: 10.1016/S0344-0338(88)80043-8. View

16.

Service F, McMahon M, OBrien P, Ballard D . Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991; 66(7):711-9. DOI: 10.1016/s0025-6196(12)62083-7. View

17.

Watson R, Johnston C, OHARE M, ANDERSON J, Wilson B, Collins J . The frequency of gastrointestinal endocrine tumours in a well-defined population--Northern Ireland 1970-1985. Q J Med. 1989; 72(267):647-57. View

18.

Cubilla A, HAJDU S . Islet cell carcinoma of the pancreas. Arch Pathol. 1975; 99(4):204-7. View

19.

Buchanan K, Johnston C, OHARE M, Ardill J, Shaw C, Collins J . Neuroendocrine tumors. A European view. Am J Med. 1986; 81(6B):14-22. DOI: 10.1016/0002-9343(86)90581-4. View

20.

Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday T . Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005; 80(4):502-6. DOI: 10.4065/80.4.502. View